🔥Telegram İfşa

September is #BloodCancerAwarenessMonth, a time to raise awareness of the significant unmet need for patients with #BloodCancer. We are proud to advance our TCR-T therapy candidates, TSC-100 and TSC-101, for patients with #AML, #ALL, and #MDS undergoing allogeneic HCT.

What a night! Our Charity Casino Night raised over $20,000 for St. Jude Children’s Hospital. #TScanners enjoyed games, a silent auction, and amazing raffle prizes. Thank you to everyone who joined us and contributed to this meaningful cause! #TScan #UnleashImmunity

Today is #WorldCancerResearchDay. Every day, our team supports #CancerResearch by working to advance potentially life-changing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for patients with #Cancer. Explore our pipeline: bit.ly/4bdd4dp #CellTherapy

Today we announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer 39th Annual Meeting being held November 6 - 10 in Houston, TX and virtually. Learn more: bit.ly/3BFrDK8 #SITC24 #CellTherapy

Thank you Nature Biotechnology for featuring us in an article and speaking with our CEO, Gavin MacBeath, PhD, about our approach to provide customized multiplex TCR-T therapies for a variety of #Cancers. Read the article: bit.ly/48dW3zH #SolidTumors #CellTherapy

We had the incredible opportunity to hear from some of our TScanners in our latest installment of #CareerJourneys, as they shared their unique paths and experiences that led them to #TScan! Every journey is valuable, and it was inspiring to learn from their stories.

Today we announced that data from the ALLOHA™ Phase 1 trial will be featured in an oral presentation at #ASH24 on 12/9. Join our virtual KOL event on 12/10 at 8:00 a.m. ET where we'll discuss the data presented at the meeting. Learn more: bit.ly/3UH9gez

Happy #NationalSTEMDay! At #TScan, we know that STEM is a driving force behind innovation in biotech. To celebrate and inspire the next generation of STEM talent, we heard from some of our #TScanners on the importance of STEM and what it means to them to be part of this field.

Today we reported third quarter financial results and provided a corporate update. Read the press release to learn more about our recent accomplishments and upcoming anticipated milestones: bit.ly/3Z4LzzD #CellTherapy #UnleashImmunity #TCells

TScan is proud to be named to the 2024 Top Workplaces list for Appreciation, Employee Well-Being, and Professional Development! This recognition is thanks to invaluable feedback from #TScanners. We’re grateful for this honor and the people who made it possible. #TopWorkplaces

Yesterday we announced we’ll host a virtual KOL event on 12/10 at 8am ET to discuss data from the ALLOHA™ Phase 1 trial presented at #ASH24, our clinical development strategy for the heme program and an update on the PLEXI-T™ Phase 1 solid tumor trial. bit.ly/4ghDzkx

For the third year, we’re one of The Boston Globe’s 2024 Top Places to Work! This achievement reflects our commitment to creating an inclusive environment and dedication to improving the lives of patients with #Cancer. Thank you to our team! bit.ly/49mdxKq

We’ll be presenting preliminary results from the ALLOHA™ Phase 1 trial of TSC-100 and TSC-101 in #AML, #ALL, and #MDS at #ASH24. Join our virtual KOL event on 12/10 at 8am ET, where we'll discuss the data presented at ASH and more! Register here: bit.ly/4gc97YU

Today we announced updated data from the ongoing ALLOHA™ Phase 1 heme trial being presented in an oral session at #ASH24. Read the press release to learn more and join our virtual KOL event tomorrow where we will discuss these data. bit.ly/4gqzydz

Today we announced that we have entered into a $30 million registered direct offering at a 37% premium with Lynx1 Capital Management and an investment fund advised by Lynx1. Read the press release to learn more: bit.ly/4gu5fTv #CellTherapy #Biotech

We look forward to being in San Francisco next week during #JPM2025! Connect with us to learn more about our recent progress and exciting plans for 2025. #CellTherapy #TCells #Biotech

On #WorldCancerDay, we reflect on our Mission Wall and the submissions from our #TScanners that tell a personal story of how cancer has impacted their lives, reminding us that we are #UnitedByUnique. More about our programs targeting various cancers: bit.ly/4bdd4dp

Honoring women and girls in science today and every day! At TScan, we celebrate the talented women driving progress in science. #WomenInScience #GirlsInSTEM

Today we announced that the Company will participate in a fireside chat at the H.C. Wainwright & Co. 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:00 a.m. ET. Learn more: bit.ly/4k0lnP1 #CellTherapy #TCells

This month, #TScanners came together as TSpinners to ride for a cause that's close to our hearts! We raised over $23,000 participating in Cycle for Survival, the official rare cancer fundraising program of MSK Cancer Center #CycleForSurvival #RareCancer #MSK